Biomarker Market
Biomarker Market Size, Share & Trends Analysis by Type (Genomic Biomarker, and Protein Biomarker) By Application (Drug Discovery & Development, Diagnostic, Prognostic, Predictive, and Others ) By Disease (Cancer, Cardiac, Renal, Central Nervous System Disease, and Others) By End-User (Hospitals, Diagnostic Centre, and Research Institute), Forecast Period (2026-2035)
Industry Overview
Biomarker market was valued at $52 billion in 2025 and is projected to reach $141.7 billion by 2035, growing at a CAGR of 10.7% during the forecast Period (2026-2035). The market is driven by demand for personalized medicine, rising chronic diseases (cancer, neurodegenerative), tech advancements (AI, omics, liquid biopsies), and increased R&D investment. Key factors fueling this growth are better early disease detection, targeted therapies (companion diagnostics), and improved clinical decision-making.
Market Dynamics
Growth of Precision Medicine & Companion Diagnostics
The shift from one-size-fits-all treatments toward precision/targeted therapies is driving demand for biomarkers that predict disease, prognosis and drug response. Biomarkers are now integral to companion diagnostics used in oncology and other therapeutic areas, which increases clinical adoption and commercial partnership activity between diagnostics firms and pharma.
Technological Advances in Omics, NGS, and Data Analytics
Improvements and cost reductions in genomics, proteomics, transcriptomics, high-throughput sequencing (NGS), mass spectrometry, and bioinformatics (including AI/ML) have greatly accelerated biomarker discovery, validation, and multiplex testing. These technologies shorten development timelines, improve sensitivity/specificity, and expand the types of measurable biomarkers (e.g., liquid-biopsy, multi-omic signatures), unlocking new clinical applications and services.
Rising R&D Spending, Regulatory Support, and Disease Burden
Increased pharmaceutical & biotech R&D investment, along with greater public and private funding for biomarker research, plus clearer regulatory pathways for companion diagnostics, are strengthening the market. At the same time, growing prevalence of cancer and chronic diseases raises clinical need for better diagnostics and monitoring tools, creating sustained commercial demand across research services, assays and platforms.
Market Segmentation
- Based on the types, the market is segmented into genomic biomarker and protein biomarker.
- Based on the application, the market is segmented into drug discovery & development, diagnostic, prognostic, predictive, and others.
- Based on the disease, the market is segmented into cancer, cardiac, renal, central nervous system disease, and others.
- Based on the end-user, the market is segmented into hospitals, diagnostic centre, and research institute.
Drug Discovery and Development Segment to Grow at a Considerable Market Share
Among all segments, drug discovery and development under the application category represents the largest and leading segment in the global biomarker market. This dominance is driven by the critical role biomarkers play across the entire drug development lifecycle, from target identification and validation to lead optimization, clinical trial design, and post-marketing surveillance. Pharmaceutical and biotechnology companies increasingly rely on genomic and protein biomarkers to improve clinical trial success rates, reduce development timelines, and minimize late-stage failures by enabling patient stratification and precision medicine approaches.
The rising investment in oncology, immunology, and rare disease pipelines, coupled with the growing adoption of companion diagnostics and regulatory encouragement for biomarker-based trials, further strengthens this segment’s leadership. Additionally, advancements in high-throughput sequencing, proteomics, and bioinformatics have significantly expanded biomarker applications in drug discovery, making this segment the primary revenue contributor and the key growth driver of the global biomarker market.
Genomic Biomarker: A Key Segment in Market Growth
Among all segments in the global biomarker market, the genomic biomarker segment is expected to witness the highest growth over the forecast period. This strong growth is primarily driven by the increasing adoption of precision medicine and targeted therapies, particularly in oncology. Genomic biomarkers play a critical role in identifying specific genetic mutations associated with cancer, enabling clinicians to tailor treatments to individual patients. The rising prevalence of chronic diseases such as cancer, cardiac disorders, and central nervous system diseases further fuels demand, as these conditions require advanced diagnostic tools for early detection and effective management.
Moreover, advancements in next-generation sequencing (NGS) technologies and decreasing costs of genomic testing have made these biomarkers more accessible to a wider patient population, thereby accelerating market adoption. Research institutes and hospitals are increasingly integrating genomic biomarker testing into routine clinical practice, while pharmaceutical companies leverage these biomarkers in drug development and clinical trials to improve efficacy and reduce adverse effects. Collectively, these factors position genomic biomarkers as the key growth driver in the global biomarker market, outpacing protein biomarkers and other segments, with significant potential in both developed and emerging markets.
Regional Outlook
The global biomarker market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global biomarker market, holding the largest share due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of major biotechnology and pharmaceutical companies. The country has been at the forefront of precision medicine, with significant investments in genomics, proteomics, and biomarker research. The presence of leading research institutes, such as the National Institutes of Health (NIH), and collaborations between academia and industry have further accelerated biomarker development and commercialization. Moreover, favorable regulatory frameworks, including support from the FDA for biomarker-based diagnostics and therapies, have encouraged innovation and market expansion. The rising prevalence of chronic and lifestyle-related diseases, such as cancer, cardiovascular disorders, and central nervous system diseases, has also driven the demand for early and accurate diagnostic tools, further boosting market growth in the US.
Additionally, increased government funding for personalized medicine initiatives and extensive clinical research activities contribute to the country’s dominant position. The combination of technological advancement, strong R&D capabilities, and a robust healthcare system ensures that the United States continues to lead the global biomarker market, setting trends that influence adoption and growth in other regions such as Europe and Asia-Pacific.
Market Players Outlook
The major companies operating in the global biomarker market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In December 2025, Lunit partnered with Daiichi Sankyo to enhance AI-driven biomarker discovery and translational oncology research. This collaboration will utilize Lunit SCOPE digital pathology products in two oncology pipeline programs, where Daiichi Sankyo will implement solutions such as SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis. The goal is to identify novel biomarkers that could improve clinical trials and support precision patient stratification.
- In November 2025, Servier India launched a biomarker testing initiative for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) patients, in partnership with MedGenome and Strand Life Sciences. This program aims to enhance access to molecular testing throughout India by offering a customized panel of tests at subsidized rates. Notably, IDH1 and IDH2 mutation testing will be provided free of charge for the government sector. The initiative targets the healthcare professionals in both private and government sectors, addressing the existing disparities in access to advanced diagnostics, particularly in urban populations.
- In August 2025, Aptamer launched a biomarker discovery service aimed at researchers in pharmaceuticals, biotechnology, and diagnostics. This service combines Aptamer’s Optimer technology with proteomic analysis for an unbiased, high-throughput method of biomarker identification and validation. The methodology allows for simultaneous identification of biomarkers and the generation of specific affinity ligands, known as aptamers. Utilizing Optimers, which are synthetic oligonucleotide molecules with improved stability and binding specificity, the platform differentiates healthy from diseased samples. It facilitates precise identification of molecular biomarkers, providing validated biomarkers and applicable aptamers or the option to explore alternatives like antibodies.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global biomarker market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Biomarker Market Sales Analysis – Type | Application | Disease | End-User ($ Million)
- Biomarker Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Biomarker Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Biomarker Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Biomarker Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Biomarker Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Biomarker Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Biomarker Market Revenue and Share by Manufacturers
- Biomarker Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Abbott Laboratories
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Illumina, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Thermo Fisher Scientific, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- QIAGEN N.V.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Abbott Laboratories
- Key Company Analysis
- Global Biomarker Market Sales Analysis by Types ($ Million)
- Genomic Biomarker
- Protein Biomarker
- Global Biomarker Market Sales Analysis by Application ($ Million)
- Drug Discovery and Development
- Diagnostic
- Prognostic
- Predictive
- Others (Risk Assessment)
- Global Biomarker Market Sales Analysis by Disease ($ Million)
- Cancer
- Cardiac
- Renal
- Central Nervous System Disease
- Others (Nash)
- Global Biomarker Market Sales Analysis by End-User ($ Million)
- Hospitals
- Diagnostic Centre
- Research Institute
- Regional Analysis
- North American Biomarker Market Sales Analysis – Type | Application | Disease | End-User | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Biomarker Market Sales Analysis – Type | Application | Disease | End-User | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Biomarker Market Sales Analysis – Type | Application | Disease | End-User | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Biomarker Market Sales Analysis – Type | Application | Disease | End-User | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Agilent Technologies, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Becton, Dickinson and Company (BD)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- bioMérieux SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bio-Rad Laboratories, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Charles River Laboratories International Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Danaher Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eurofins Scientific
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Exact Sciences Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Guardant Health, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hologic, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Illumina, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Myriad Genetics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- PerkinElmer Inc. (Revvity)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- QIAGEN N.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Quest Diagnostics Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Siemens Healthineers AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Biomarker Market Research and Analysis by Types, 2025–2035 ($ Million)
2. Global Genomic Biomarker Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Protein BiomarkerMarket Research And Analysis By Region, 2025–2035 ($ Million)
4. Global Biomarker Market Research and Analysis by Application, 2025–2035 ($ Million)
5. Global Biomarker In Drug Discovery And Development Market Research And Analysis By Region, 2025–2035 ($ Million)
6. Global Biomarker In Diagnostic Market Research And Analysis By Region, 2025–2035 ($ Million)
7. Global Biomarker In Prognostic Market Research And Analysis By Region, 2025–2035 ($ Million)
8. Global Biomarker In Predictive Market Research And Analysis By Region, 2025–2035 ($ Million)
9. Global Other Application Applications Market Research And Analysis By Region, 2025–2035 ($ Million)
10. Global Biomarker Market Research and Analysis by Disease, 2025–2035 ($ Million)
11. Global Biomarker In Cancer Disease Market Research And Analysis By Region, 2025–2035 ($ Million)
12. Global Biomarker In Cardiac Market Research And Analysis By Region, 2025–2035 ($ Million)
13. Global Biomarker In Renal Market Research And Analysis By Region, 2025–2035 ($ Million)
14. Global Biomarker In Central Nervous System Disease Market Research And Analysis By Region, 2025–2035 ($ Million)
15. Global Biomarker In Other Disease Market Research And Analysis By Region, 2025–2035 ($ Million)
16. Global Biomarker Market Research and Analysis by End-User, 2025–2035 ($ Million)
17. Global Biomarker For Hospital Market Research And Analysis By Region, 2025–2035 ($ Million)
18. Global Biomarker For Diagnostic Centre Market Research And Analysis By Region, 2025–2035 ($ Million)
19. Global Biomarker For Research Institute Market Research And Analysis By Region, 2025–2035 ($ Million)
20. Global Biomarker Market Research and Analysis by Region, 2025–2035 ($ Million)
21. North American Biomarker Market Research and Analysis by Types, 2025–2035 ($ Million)
22. North American Biomarker Market Research and Analysis by Application, 2025–2035 ($ Million)
23. North American Biomarker Market Research and Analysis by Disease, 2025–2035 ($ Million)
24. North American Biomarker Market Research and Analysis by End-User, 2025–2035 ($ Million)
25. European Biomarker Market Research and Analysis by Types, 2025–2035 ($ Million)
26. European Biomarker Market Research and Analysis by Application, 2025–2035 ($ Million)
27. European Biomarker Market Research and Analysis by Disease, 2025–2035 ($ Million)
28. European Biomarker Market Research and Analysis by End-User, 2025–2035 ($ Million)
29. Asia-Pacific Biomarker Market Research and Analysis by Types, 2025–2035 ($ Million)
30. Asia-Pacific Biomarker Market Research and Analysis by Application, 2025–2035 ($ Million)
31. Asia-Pacific Biomarker Market Research and Analysis by Disease, 2025–2035 ($ Million)
32. Asia-Pacific Biomarker Market Research and Analysis by End-User, 2025–2035 ($ Million)
33. Rest of the World Biomarker Market Research and Analysis by Region, 2025–2035 ($ Million)
34. Rest of the World Biomarker Market Research and Analysis by Types, 2025–2035 ($ Million)
35. Rest of the World Biomarker Market Research and Analysis by Application, 2025–2035 ($ Million)
36. Rest of the World Biomarker Market Research and Analysis by Disease, 2025–2035 ($ Million)
37. Rest of the World Biomarker Market Research and Analysis by End-User, 2025–2035 ($ Million)
1. Global Biomarker Market Share By Types, 2025 Vs 2035 (%)
2. Global Genomic Biomarker Market Share By Region, 2025 Vs 2035 (%)
3. Global Protein Biomarker Market Share By Region, 2025 Vs 2035 (%)
4. Global Biomarker Market Share By Application, 2025 Vs 2035 (%)
5. Global Biomarker In Drug Discovery And Development Market Share By Region, 2025 Vs 2035 (%)
6. Global Biomarker In Diagnostic Market Share By Region, 2025 Vs 2035 (%)
7. Global Biomarker In Prognostic Market Share By Region, 2025 Vs 2035 (%)
8. Global Biomarker In Predictive Market Share By Region, 2025 Vs 2035 (%)
9. Global Other Application Biomarker Market Share By Region, 2025 Vs 2035 (%)
10. Global Biomarker Market Share By Disease, 2025 Vs 2035 (%)
11. Global Biomarker In Cancer Disease Market Share By Region, 2025 Vs 2035 (%)
12. Global Biomarker In Cardiac Disease Market Share By Region, 2025 Vs 2035 (%)
13. Global Biomarker In Renal Disease Market Share By Region, 2025 Vs 2035 (%)
14. Global Biomarker In Central Nervous System Disease Market Share By Region, 2025 Vs 2035 (%)
15. Global Biomarker In Other Disease Market Share By Region, 2025 Vs 2035 (%)
16. Global Biomarker Market Share By End-User, 2025 Vs 2035 (%)
17. Global Biomarker Market Share For Hospitals By Region, 2025 Vs 2035 (%)
18. Global Biomarker Market Share For Diagnostic Centres By Region, 2025 Vs 2035 (%)
19. Global Biomarker Market Share For Research Institutes By Region, 2025 Vs 2035 (%)
20. Global Biomarker Market Share By Region, 2025 Vs 2035 (%)
21. Us Biomarker Market Size, 2025–2035 ($ Million)
22. Canada Biomarker Market Size, 2025–2035 ($ Million)
23. Uk Biomarker Market Size, 2025–2035 ($ Million)
24. France Biomarker Market Size, 2025–2035 ($ Million)
25. Germany Biomarker Market Size, 2025–2035 ($ Million)
26. Italy Biomarker Market Size, 2025–2035 ($ Million)
27. Spain Biomarker Market Size, 2025–2035 ($ Million)
28. Russia Biomarker Market Size, 2025–2035 ($ Million)
29. Rest Of Europe Biomarker Market Size, 2025–2035 ($ Million)
30. India Biomarker Market Size, 2025–2035 ($ Million)
31. China Biomarker Market Size, 2025–2035 ($ Million)
32. Japan Biomarker Market Size, 2025–2035 ($ Million)
33. South Korea Biomarker Market Size, 2025–2035 ($ Million)
34. Australia And New Zealand Biomarker Market Size, 2025–2035 ($ Million)
35. Asean Economies Biomarker Market Size, 2025–2035 ($ Million)
36. Rest Of Asia-Pacific Biomarker Market Size, 2025–2035 ($ Million)
37. Latin America Biomarker Market Size, 2025–2035 ($ Million)
38. Middle East And Africa Biomarker Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Biomarker Market in 2025 is estimated to be around $52 billion.
North America holds the largest share in the Biomarker Market.
Leading players in the Biomarker Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., among others.
The Biomarker Market is expected to grow at a CAGR of 10.7% from 2026 to 2035.
The Biomarker Market is driven by rising demand for precision medicine and increasing adoption of advanced diagnostic technologies.
